Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Inflammation and the immune system

Topic: Brain proteins, microglia and lab models

Plain-language summary

Alzheimer's disease is the world's most common dementing illness. Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events.

What this study adds

Evidence grade: Low

This study reports "strongly enhanced active caspase-1" in the brains of people with mild cognitive impairment and Alzheimer's disease, which the authors say suggests a role for the inflammasome in the disease. Its title adds that NLRP3 "contributes to pathology in APP/PS1 mice", but alzhub's stored summary does not describe the mouse experiments.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., et al. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. https://doi.org/10.1038/nature11729

Vancouver

Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013. doi:10.1038/nature11729. PMID: 23254930.

BibTeX

@article{heneka2013-23254930,
  author  = {Heneka, M. T. and Kummer, M. P. and Stutz, A. and Delekate, A. and Schwartz, S. and Vieira-Saecker, A. and Griep, A. and Axt, D. and others},
  title   = {{NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice}},
  journal = {Nature},
  year    = {2013},
  doi     = {10.1038/nature11729},
  pmid    = {23254930},
  url     = {https://doi.org/10.1038/nature11729}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study reports "strongly enhanced active caspase-1" in the brains of people with mild cognitive impairment and Alzheimer's disease, which the authors say suggests a role for the inflammasome in the disease. Its title adds that NLRP3 "contributes to pathology in APP/PS1 mice", but alzhub's stored summary does not describe the mouse experiments. The human result is an association in brain tissue with no numbers given here, so it does not show that NLRP3 causes Alzheimer's or that blocking it would help patients.

Study details

How this study scored 62/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 62 of 100.62 of 100 points earned38 not earned

Published in a top-tier journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Nature)
Journal's citation record 4 / 4 Nature: journal h-index 1,841 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Laboratory or animal study (title names “app/ps1”) — scores zero
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 2,881 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 192.1 citations a year over 15 year(s) since 2013
Impact for its field and year 5 / 6 Cited 31.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 81 other studies in this library
Still being cited 4 / 4 Cited 785 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Douglas Taylor Golenbock: h-index 129 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Bonn: institution h-index 1,072 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 8 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23254930)
Free to read 2 / 2 Free to read
Total 62 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

81 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Inflammation and the immune system from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →